Torrent Pharma's second quarter earnings are anticipated to fall because of high base in year-ago period. Profit will hopefully sink 51.8 per cent year-on-year to Rs 273.7 crore and revenue can fall 8.9 per cent to Rs 1,540.7 crore in Q2,as per analysts. Sales from mental health drug Abilify generic gave a positive impact to the earnings in FY16. In Q2FY16, sales were up 38.9 per cent to Rs 1,691 crore, EBITDA increased by 162 per cent with margin at 42.2 perc ent (as compared to 22.4 per cent Y-o-Y) and profit up 187 per cent.
Thus, revenue fell 20 per cent in Q1FY17 which is likely to continue in Q2 as well. Operating profit is seen to fall 39.2 per cent year-on-year to Rs 434.3 crore and margin can shrink 1,400 basis points to 28.2 per cent in Q2. US business will hopefully decline around 40-50 per cent Y-o-Y as Q2FY16 US sales benefited from Abilify generic. US sales in Q1 were down 51 per cent to Rs 434 crore Y-o-Y. India business will grow around 10-15 per cent onm account of integration of Elder's portfolio.
Torrent Pharma share price tanked 0.70 per cent intraday on Tuesday. The stock settled at Rs. 1600.90, touched the day’s high and low at Rs. 1630 and Rs. 1595.05. Last day around 72,928 shares were traded in the counter with a traded value of Rs. 1,171.92 lacs, as per NSE.
The market cap of the company amounts to Rs. 27091.06 (Cr) and has a book value of Rs. 200.27.
The market cap of the company amounts to Rs. 27091.06 (Cr) and has a book value of Rs. 200.27.
Torrent Pharmais analyzed by Dynamic Levels as the top 500 performing stocks for this quarter among the 1700 stocks which are listed on the NSE. Torrent Pharma is fundamentally strong and is safe for investment, as per Dynamic analysts.
In order to know about the support and resistance levels of the scrip and also its fundamentals and financials, please a pay a visit to Torrent Pharma share price history.
No comments:
Post a Comment